Karxt
Autism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyunclassifiedPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Autism-Related Irritability cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Holland Bloorview Kids Rehabilitation Hospital | Phase 4 | BBB |
Risperdal Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BB |
Cariprazine AbbVie | Phase 3 | BB |
Lumateperone Intra-Cellular Therapies, Inc. | Phase 3 | B |
Betahistine Nathan Kline Institute for Psychiatric Research | Phase 2 | B |
View all 15 →
Same molecule, other indications
Karxt is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →